Indegene Limited — Q2FY27 earnings call summary

Filed 03 November 2026 · Official transcript

Q2 FY27 revenue INR11,223 million +39.5% y-y, EBITDA margin 16.7%, PAT margin 10%
EBITDA margin expected 19%+ by Q4; wage hikes absorbed, productivity gains ongoing
BioPharm acquisition integration progressing; $1.5m cost synergies reinvested
Industry tailwinds: capital up 85% y-y, record drug approvals, larger complex pipeline
9 deal wins including $5m+ and $3-5m deals; Tectonic model expanding to Canada
Outcome-based contracts growing; $10m+ deal ramping in Q4 impacting margins
Largest client revenue stable; top 20 accounts grew 6.7% sequentially
AI-led Agentic AOR and Tectonic driving upstream growth and new business